Fuji Pharma Co., Ltd.
Notice Concerning Distribution of Surplus (Dividend Increase)
Based on full-year results for the fiscal year ending September 2026, the company has revised upward the year-end dividend by 29 yen per share effective December 21, 2026. The annual dividend is planned at 52 yen. This is an increase of 6 yen 50 sen compared with the previous fiscal year result of 45 yen 50 sen.
Key Figures
- Dividend per Share: 29 yen 00 sen
- Annual Dividend Forecast: 52 yen 00 sen
- Total Dividend Amount: 758 million yen
AI要約
Dividend Policy and Implementation
Fuji Pharma Co., Ltd. has a dividend policy of allocating profits based on consolidated results, aiming for a payout ratio of approximately 30% on post-tax operating profit excluding special factors, and seeks to provide stable and continuous dividends. As full-year results for the fiscal year ending September exceeded expectations, the company has revised the year-end dividend upward to 29 yen and plans an annual dividend of 52 yen, with an effective date of December 21, 2026, to be proposed at the Ordinary General Meeting of Shareholders scheduled for December 18. The previous fiscal year result was 45 yen 50 sen, and this revision represents an increase of 6 yen 50 sen.
Impact on Shareholders and Outlook
This dividend increase reflects an intent to strengthen stable cash returns against a backdrop of improved consolidated results. The year-end dividend will be 29 yen and the annual dividend 52 yen, representing an increase year-on-year. The dividend will be funded from retained earnings. Depending on future performance trends, there may be further reviews of the dividend policy.
Fuji Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR